Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCING: Glyburide in Acute Traumatic Spinal Cord Injury
NCT02524379Phase 2Terminated
- Sponsor
- The Ohio State University
- Start
- Feb 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glibenclamide in spinal cord injury (SCI), sponsored by The Ohio State University. Started Feb 2017; status: terminated.
02
Drugs
glibenclamide
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02524379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524379.